Trendlines adds that the De Novo design opens up many new markets by targeting insect challenges that were previously unattainable with naturally occurring proteins, while also optimizing commercial aspects such as higher gross margins, longer shelf life, stability, and resiliency.
The Trendlines Group (Trendlines) (SGX:42T
) announced that its portfolio company, IBI Ag, successfully completed its proof of concept (POC) for the AI-driven platform for De Novo design of novel bioinsecticide proteins.
“By leveraging cutting-edge AI technology and proprietary biological data, IBI Ag has developed a novel approach to computationally design bioinsecticide proteins that selectively and effectively target pests while aiming to minimize the impact on beneficial insects and the environment,” Trendlines says.
